




RealRate

PHARMACEUTICAL 2019

Actinium Pharmaceuticals Inc
Rank 293 of 361



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Actinium Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Actinium Pharmaceuticals Inc compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 4.0% points. The greatest weakness of Actinium Pharmaceuticals Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 82% points.

The company's Economic Capital Ratio, given in the ranking table, is 139%, being 111% points below the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	14,330
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,063
Liabilities, Non-Current	0
Other Assets	441
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	13
Other Net Income	173
Other Revenues	0
Property and Equipment	119
Research and Development	17,095
Selling, General and Administrative Expense	6,733

Output Variable	Value in 1000 USD
Assets	14,889
Liabilities	6,077
Expenses	23,827
Revenues	0
Stockholders Equity	8,813
Net Income	-23,654
Comprehensive Net Income	-23,654
BaseVar	22,483
ECR before LimitedLiability	-42%
Economic Capital Ratio	139%